Nanosizing of a drug/carrageenan complex to increase solubility and dissolution rate

International Journal of Pharmaceutics

Volumn 342, Issue 1-2, 2007, Pages 201-207

  Dai, Wei Guo ^a   Dong, Liang C ^a   Song, Yan Qiu ^a  

^a ALZA CORPORATION   (United States)

Author keywords

Carrageenan; Dissolution; Drug polymeric complex; Nanosizing; Solubility

Indexed keywords

CARRAGEENAN;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

CALORIMETRY, DIFFERENTIAL SCANNING; CARRAGEENAN; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; FREEZE DRYING; KINETICS; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; X-RAY DIFFRACTION;

EID: 34547861305     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.04.032     Document Type: Article

References (21)

1. Aguzzi C., Bonferoni Maria C., Fortich Maria Rosario O., Rossi S., Ferrari F., and Caramella C. Influence of complex solubility on formulations based on lambda carrageenan and basic drugs. AAPS Pharm. Sci. Technol. 3 (2002) E27
2. Bertram U., and Bodmeier R. In situ gelling, bioadhesive nasal inserts for extended drug delivery: in vitro characterization of a new nasal dosage form. Eur. J. Pharm. Sci. 27 (2006) 62-71
3. Bonferoni M.C., Chetoni P., Giunchedi P., Rossi S., Ferrari F., Burgalassi S., and Caramella C. Carrageenan-gelatin mucoadhesive systems for ion-exchange based ophthalmic delivery: in vitro and preliminary in vivo studies. Eur. J. Pharm. Biopharm. 57 (2004) 465-472
4. Bonferoni M.C., Rossi S., Ferrari F., and Caramella C. Development of oral controlled-release tablet formulations based on diltiazem-carrageenan complex. Pharm. Dev. Technol. 9 (2004) 155-162
5. Bonferoni M.C., Rossi S., Ferrari F., Stavik E., Pena-Romero A., and Caramella C. Factorial analysis of the influence of dissolution medium on drug release from carrageenan-diltiazem complexes. AAPS Pharm. Sci. Technol. 1 (2000) E15
6. In: Brittain H.G. (Ed). Physical Characterization of Pharmaceutical Solids (1995), Dekker, New York
7. De Jaeghere F., Allemann E., Doelker E., Gurny R., Cerny R., Galli B., Steulet A.F., Mueller I., and Schuetz H. pH-dependent dissolving nano- and microparticles for improved peroral delivery of a highly lipophilic compound in dogs. AAPS Pharm. Sci. 3 (2001) E8
8. Graham H.D., and Baker Y.M. Interaction of antihistamines with hydrocolloids. J. Pharm. Sci. 52 (1963) 964-967
9. Graham H.D., Baker Y.M., and Njoku-Obi A.N. Complex formation between hydrocolloids and tranquilizers and hypotensive agents. J. Pharm. Sci. 52 (1963) 192-198
10. Guiseley K.B., Stanley N.F., and Whitehouse P.A. Carrageenan. In: Davidson R.L. (Ed). Handbook of Water-soluble Gums and Resins (1980), McGraw-Hill, New York 5/1-5/30
11. Jinno J.-I., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., and Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Rel. 111 (2006) 56-64
12. Langguth P., Hanafy A., Frenzel D., Grenier P., Nhamias A., Ohlig T., Vergnault G., and Spahn-Langguth H. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev. Ind. Pharm. 31 (2005) 319-329
13. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
14. Liu R. Water-insoluble Drug Formation (2000), Interpharm Press, Buffalo Grove
15. Liversidge G.G., and Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125 (1995) 91-97
16. Merisko-Liversidge E., Liversidge G.G., and Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18 (2003) 113-120
17. Mueller R.H., and Akkar A. Drug nanocrystals of poorly soluble drugs. In: Nalwa H.S. (Ed). Encyclopedia of Nanoscience and Nanotechnology vol. 2 (2004), American Scientific Publishers, Stevenson Ranch, California 627-638
18. Muller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47 (2001) 3-19
19. Noyes A.A., and Whitney W.R. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 19 (1897) 930-934
20. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3 (2004) 785-796
21. Wu Y., Loper A., Landis E., Hettrick L., Novak L., Lynn K., Chen C., Thompson K., Higgins R., Batra U., Shelukar S., Kwei G., and Storey D. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285 (2004) 135-146